Tissue biopsy for the diagnosis of amyloidosis: experience from some centres

Lung cancer is a leading cause of cancer-related deaths, contributing to 18.4% of cancer deaths globally. Treatment of non-small cell lung carcinoma has seen rapid progression with targeted therapies tailored to specific genetic drivers. However, identifying genetic alterations can be difficult due to lack of tissue, inaccessible tumors and the risk of complications for the patient with serial tissue sampling. The liquid biopsy provides a minimally invasive method which can obtain circulating biomarkers shed from the tumor and could be a safer alternative to tissue biopsy. While tissue biopsy remains the gold standard, liquid biopsies could be very beneficial where serial sampling is required, such as monitoring disease progression or development of resistance mutations to current targeted therapies. Liquid biopsies also have a potential role in identifying patients at risk of relapse post treatment and as a component of future lung cancer screening protocols. Rapid developments have led to multiple platforms for isolating circulating tumor cells (CTCs) and detecting circulating tumor DNA (ctDNA); however, standardization is lacking, especially in lung carcinoma. Additionally, clonal hematopoiesis of uncertain clinical significance must be taken into consideration in genetic sequencing, as it introduces the potential for false positives. Various biomarkers have been investigated in liquid biopsies; however, in this review, we will concentrate on the current use of ctDNA and CTCs, focusing on the clinical relevance, current and possible future applications and limitations of each.

Download Full-text

Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients

EJNMMI Research ◽

10.1186/s13550-020-00732-z ◽

2020 ◽

Vol 10 (1) ◽

Author(s):

Amin Haghighat Jahromi ◽

Donald A. Barkauskas ◽

Matthew Zabel ◽

Aaron M. Goodman ◽

Garret Frampton ◽

...

Keyword(s):

Fdg Pet ◽

Standardized Uptake Value ◽

Emission Tomography ◽

Maximum Standardized Uptake Value ◽

Tissue Biopsy ◽

Mutational Burden ◽

Positron Emission ◽

Pet Ct ◽

Tumor Mutational Burden ◽

Fdg Pet Ct

Abstract Purpose Deriving links between imaging and genomic markers is an evolving field. 2-[18F]FDG PET/CT (18F-fluorodeoxyglucose positron emission tomography–computed tomography) is commonly used for cancer imaging, with maximum standardized uptake value (SUVmax) as the main quantitative parameter. Tumor mutational burden (TMB), the quantitative variable obtained using next-generation sequencing on a tissue biopsy sample, is a putative immunotherapy response predictor. We report the relationship between TMB and SUVmax, linking these two important parameters. Methods In this pilot study, we analyzed 1923 patients with diverse cancers and available TMB values. Overall, 273 patients met our eligibility criteria in that they had no systemic treatment prior to imaging/biopsy, and also had 2-[18F]FDG PET/CT within 6 months prior to the tissue biopsy, to ensure acceptable temporal correlation between imaging and genomic evaluation. Results We found a linear correlation between TMB and SUVmax (p < 0.001). In the multivariate analysis, only TMB independently correlated with SUVmax, whereas age, gender, and tumor organ did not. Conclusion Our observations link SUVmax in readily available, routinely used, and noninvasive 2-[18F]FDG PET/CT imaging to the TMB, which requires a tissue biopsy and time to process. Since higher TMB has been implicated as a prognostic biomarker for better outcomes after immunotherapy, further investigation will be needed to determine if SUVmax can stratify patient response to immunotherapy.

Download Full-text

High Accuracy of Second Generation Unyvero ITI Automated Multiplex PCR Analysis of Joint Fluid Aspirate in Low-Grade Prosthetic Hip and Knee Joint Infections

Orthopaedic Journal of Sports Medicine ◽

10.1177/2325967120s00303 ◽

2020 ◽

Vol 8 (5_suppl4) ◽

pp. 2325967120S0030

Author(s):

Christian Suren ◽

Susanne Feihl ◽

Sabrina Cabric ◽

Ingo Banke ◽

Bernhard Haller ◽

...

Keyword(s):

Multiplex Pcr ◽

Revision Surgery ◽

Second Generation ◽

Joint Fluid ◽

Low Grade ◽

Tissue Biopsy ◽

Conventional Culture ◽

Joint Infections ◽

Prosthetic Joint ◽

Fluid Culture

Aims and Objectives: A major obstacle for the treatment of prosthetic joint infections (PJIs) is the identification of the organism causing it. While the diagnostic criteria ruling PJIs in or out have become ever more accurate, detecting the causative pathogen(s) still relies mostly on conventional culture. The aim of this study was to evaluate the diagnostic potential of a second generation multiplex PCR assay (Unyvero ITI G2, Curetis AG, Holzgerlingen, Germany) used on synovial fluid specimens. Materials and Methods: Prospectively collected frozen joint fluid specimens from 26 patients undergoing arthroplasty revision surgery of the hip or knee for any reason were tested as per the manufacturer’s protocol. The sensitivity and specificity were calculated using the Chi-squared-test and a combination of the serum CRP level, leukocyte count, erythrocyte sedimentation rate, joint fluid culture, tissue biopsy culture, and tissue biopsy histology served as gold standard. Results: Of the 26 cases included in the study, 15 were infected and 11 aseptic. Conventional joint fluid culture showed a sensitivity 0.67 and a specificity of 0.91. Joint fluid multiplex PCR yielded a sensitivity of 0.8 and a specificity of 1.0. Conclusion: This is the first study to assess the second generation Unyvero ITI cartridge on joint fluid aspirate for the detection of prosthetic joint infection. In our setting, the method achieved a higher diagnostic accuracy than conventional culture. We conclude that, to improve pathogen detection before revision surgery, this method represents a valuable tool.

Download Full-text

Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy

BMC Cancer ◽

10.1186/s12885-018-4222-z ◽

2018 ◽

Vol 18 (1) ◽

Cited By ~ 4

Author(s):

Isa Mambetsariev ◽

Lalit Vora ◽

Kim Wai Yu ◽

Ravi Salgia

Keyword(s):

Liquid Biopsy ◽

Mutation Detection ◽

Tissue Biopsy

Download Full-text

Application of the minimal trauma tissue biopsy to transdermal clinical pharmacokinetic studies

Journal of Controlled Release ◽

10.1016/s0168-3659(01)00394-7 ◽

2001 ◽

Vol 75 (3) ◽

pp. 297-306 ◽

Cited By ~ 11

Author(s):

Claudia Schrolnberger ◽

Martin Brunner ◽

Bernhard X. Mayer ◽

Hans G. Eichler ◽

Markus Müller

Keyword(s):

Clinical Pharmacokinetic ◽

Pharmacokinetic Studies ◽

Tissue Biopsy ◽

Minimal Trauma

Download Full-text

A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detection

BMC Urology ◽

10.1186/1471-2490-12-16 ◽

2012 ◽

Vol 12 (1) ◽

Cited By ~ 30

Author(s):

Leander Van Neste ◽

Joseph Bigley ◽

Adam Toll ◽

Gaëtan Otto ◽

James Clark ◽

...

Keyword(s):

Prostate Cancer ◽

Multiplex Pcr ◽

Cancer Detection ◽

Pcr Assay ◽

Prostate Cancer Detection ◽

Tissue Biopsy ◽

Multiplex Pcr Assay

Download Full-text

Circulating tumor cell proportion scoring (CTPS) based PD-L1 assessment and clinical application of circulating tumor cells (CTCs) on stage IV non-small cell lung cancer (NSCLC) through liquid biopsy.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.e15031 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. e15031-e15031

Author(s):

Mi Young Choi ◽

Da Hye Moon ◽

Jong-min Jo ◽

Hae Ung Lee ◽

Seri Park ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

False Positive ◽

Stage Iv ◽

Small Cell ◽

Advanced Lung Cancer ◽

Diagnostic Strategy ◽

Small Cell Lung ◽

Tissue Biopsy

e15031 Background: Stage IV lung cancer is the most advanced lung cancer state accompanied by metastasized to the area around the lungs or distant major organs. The most common type of lung cancer is non-small cell lung cancer, which is more aggressive and may spread quickly due to organ-specific complex networks such as lymph and major blood vessels. Thus, only precise diagnostic strategy approaches will determine the effectiveness of the actual and successful clinical treatment. Until a recent date, Immunohistochemistry (IHC) for programmed death-ligand 1(PD-L1) test is the only available biomarker test that purpose diagnostics (CDx) and guide the treatment with immune checkpoint inhibitors in NSCLC. Methods: Given that CDx strategy, tissue biopsy has inevitable limitations, including patient risk, repetitive examination, sample preparation, sensitivity, and accuracy. For this reason, our research team contrived the best strategy for biomarker, PD-L1-specific CTCs in stage IV NSCLC group (N = 30) compared to pulmonary inflammatory patient groups (N = 30) CytoGen Smart biopsy platform. Herein, we removed false-positive cells for the first strategy of distinguishing between lymphoid/myeloid cells and the enriched-CTCs. And the second strategic approach is to calculate the pure CTCs (without false-positive cells) and then CTPS) as measured by the PD-L1 expression among pure-CTCs. That application is the percentage of viable CTCs showing partial or complete stained cells at the deducted cut-off value in each fluorescence, respectively. Results: Consequently, we demonstrated over 80% of the concordance rate between VENTANA PD-L1(SP263) and DAKO PD-L1(SP263) assay tested by the PD-L1 expression on stage IV NSCLC in tissue and pure-CTCs based CTPS from the blood. In contrast, pure-CTCs based CTPS in the pulmonary inflammatory group were all negative (recorded as zero). Conclusions: Conclusively, this study implicates that pure-CTCs based CTPS could be deployed for innovative diagnosis strategies as alternatives for tissue biopsy. Our clinical study's data suggested that the possibility for prompt decision for diagnosis and gain powerful insights to guide the personalized treatment in NSCLCs. Clinical trial information: 2020-0553.

Download Full-text